Table 1.
Sociodemographic and clinical characterization of patients with atrial fibrillation using warfarin (n=317)
| Variable | Total | Group 1, n=98 |
Group 2, n=74 |
Group 3, n=94 |
Group 4, n=51 |
Test χ2 (p-value) |
|---|---|---|---|---|---|---|
| Sociodemographic | ||||||
| Age (mean ± sd) | 60.63±16.11 | 60.26±11.32 | 60.32±12.7 | 64.19±12.59 | 62.59±12.37 | 0.1 |
| Sex | ||||||
| Male | 151 (47.6) | 57 (58) | 25(34) | 42 (45) | 27 (53) | 0.02 |
| Female | 166 (52.4) | 41 (42) | 49 (66) | 52 (55) | 24 (47) | |
| Color/race* | ||||||
| White | 78 (25) | 20 (20.4) | 17 (23) | 27 (28.7) | 14 (27.5) | 0.93 |
| Brown | 188 (59) | 62 (63.3) | 44 (59.5) | 51 (54.3) | 31 (60.8) | |
| Black | 51 (16) | 16 (16.3) | 13 (15.5) | 16 (17) | 6 (11.7) | |
| Clinic | ||||||
| Arterial hypertension | 281 (88.64) | 84 (85.7) | 66 (89.2) | 85 (90.43) | 46 (90.2) | 0.86 |
| Heart failure | 163 (51.24) | 61 (62.24) | 35 (47.3) | 43 (45.74) | 24 (47.1) | 0.15 |
| Coronary artery disease | 38 (12) | 12 (12.24) | 8 (10.8) | 11 (11.7) | 7 (13.73) | 0.99 |
| Valvopathy | 129 (40.7) | 41 (41.84) | 35 (47.3) | 34 (36.2) | 19 (37.25) | 0.65 |
| Diabetes | 59 (18.6) | 16 (16.33) | 14 (18.9) | 22 (23.4) | 7 (13.73) | 0.63 |
| Dyslipidemia | 135 (42.6) | 39 (39.8) | 29 (36.2) | 48 (51.06) | 19 (37.25) | 0.4 |
| Smoker | 119 (37.54) | 42 (44.86) | 25 (33.8) | 35 (37.23) | 17 (33.33) | 0.73 |
| Alcohol user | 106 (33.44) | 56 (57.14) | 49 (66.2) | 59 (62.77) | 34 (66.67) | 0.23 |
| Body mass index | ||||||
| Normal | 90 (28.4) | 24 (24.4) | 24 (32.4) | 29 (30.85) | 13 (25.5) | 0.92 |
| Overweight | 135 (42.6) | 44 (45) | 27 (36.5) | 42 (44.68) | 22 (43) | |
| Obese | 92 (29) | 30 (30.6) | 23 (32) | 23 (24.47) | 16 (31.5) | |
| Complications | ||||||
| Stroke | 77 (24.3) | 21 (21.4) | 15 (20.27) | 25 (26.6) | 16 (31.37) | <0.0001 |
| Bleeding | 7 (2.2) | 0 | 5 (6.8) | 2 (2.1) | 0 | 0.033 |
| Scores | ||||||
| CHADS2VASc <2 | 104 (32.8) | 37 (37.7) | 29 (39.1) | 25 (26.6) | 13 (25.5) | 0.14 |
| CHADS2VASc >2 | 213 (67.2) | 61 (62.3) | 45 (60.9) | 69 (73.4) | 38 (74.5) | |
| HAS-BLED <2 | 234 (73.8) | 64 (65.5) | 50 (67.5) | 75 (79.8) | 48 (94) | 0.0004 |
| HAS-BLED >2 | 83 (26.2) | 34 (34.7) | 24 (32.5) | 19 (20.2) | 3 (6) |
Notes: *Self-referenced; Group 1: TTR 0–45%; Group 2: TTR=46–60%; Group 3: TTR=61–80%; Group 4: TTR=81–100%. All statistically significant associations were highlighted in bold.
Abbreviation: TTR, time in therapeutic range.